Form 4: Collegium Pharmaceutical Director Exercises Options and Sells Shares

John Gordon Freund, a Director and 10% Owner of Collegium Pharmaceutical, Inc., exercised stock options and subsequently sold a portion of his directly held common stock on June 9, 2025.

Summary

• John Gordon Freund, a Director and 10% Owner of Collegium Pharmaceutical, Inc. (COLL), engaged in transactions on June 9, 2025.
• He exercised stock options to acquire 15,000 shares of common stock at an exercise price of $13.45 per share.
• Following the option exercise, his direct beneficial ownership increased to 77,259 shares.
• Concurrently, he sold 6,601 shares of common stock at a weighted average price of $30.624 per share, with prices ranging from $30.62 to $30.628.
• After these transactions, his direct beneficial ownership stands at 70,658 shares.
• Additionally, he indirectly holds 8,625 shares through Skyline Venture Management V, LLC and 34,788 shares through John Freund Family Partnership IV, L.P., disclaiming beneficial ownership except for his proportionate pecuniary interest in these entities.

Sentiment

Score: 6

Explanation: The director's profitable exercise of options and subsequent sale of a portion of shares is a routine event for insider compensation realization. While the sale might be viewed with slight caution by some investors, it's a common practice for liquidity and does not inherently signal negative company performance.

Positives

• The exercise of 15,000 stock options at a price of $13.45 indicates that the current market price was significantly higher than the exercise price, suggesting a profitable opportunity for the director.
• The sale price of $30.624 per share is more than double the exercise price, indicating a substantial gain on the exercised options.

Negatives

• The sale of 6,601 shares by a director and 10% owner could be perceived negatively by the market, as insider selling might suggest a lack of confidence in the company's near-term prospects, although the amount sold is relatively small compared to the total holdings.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction by a director and 10% owner of Collegium Pharmaceutical, Inc. Such filings are specific to individual trading activities and do not typically provide broader industry context or trends.

Related Party Transactions

• John G. Freund indirectly holds shares through Skyline Venture Management V, LLC, where he is a manager and shares voting and investment power.
• John G. Freund indirectly holds shares through the John Freund Family Partnership IV, L.P., where he is the trustee and beneficiary of the trust serving as the general partner.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be interpreted in various ways, from a routine liquidity event to a signal of reduced confidence, potentially influencing investor sentiment. The profitable option exercise highlights the value creation for insiders.

Key Dates

Recommendation

Keywords

Collegium Pharmaceutical, COLL, Form 4, insider trading, stock options, share sale, director transaction, beneficial ownership, John Gordon Freund, pharmaceutical